Inventors:
Rachel Wallach Humphrey - Princeton NJ, US
International Classification:
A61K 39/395, A61P 37/02, A61P 35/00
Abstract:
The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of immunotherapeutic agents e.g. CTLA-4 antagonists such as Ipilimumab or Tremelimumab in combination with one or more chemotherapeutic agents in cancer patients.